For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Patients With Newly Diagnosed Glioblastoma Treatment Study
This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.
In order to participate you must meet the following criteria:
- Have newly diagnosed glioblastoma.
- Are at least 18 years of age.
- Have no prior cancer unless disease free for ≥ 3 years.
- Have no prior chemotherapy or radiotherapy to the head and neck.
This is a partial list of inclusion and exclusion criteria.